USFDA Inspection Successfully concluded at Gland Pharma: A Closer Look

USFDA Inspection: In the dynamic pharmaceutical landscape, Gland Pharma has recently made waves with a significant announcement.

USFDA Inspection audit
USFDA Inspection

USFDA Inspection

In the dynamic pharmaceutical landscape, Gland Pharma has recently made waves with a significant announcement. The company proudly shared that it has received an Establishment Inspection Report (EIR) from the USFDA, signifying the successful closure of the USFDA inspection at its Pashamylaram Facility in Hyderabad.

Let’s delve into the details of this notable achievement and what it means for Gland Pharma’s future.

Background of Gland Pharma

Picture: Pixabay

Established in 1978 in Hyderabad, Gland Pharma has solidified its position as a prominent player in the pharmaceutical industry.

Specializing in generic injectables, the company boasts a diverse range of products, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions.

USFDA Inspection Details

The meticulous USFDA inspection occurred between August 23, 2023, and August 26, 2023.

Focused on the Quality System and Current Good Manufacturing Practice regulations for Medical Devices (21 CFR Part 820), the inspection aimed to ensure compliance with stringent industry standards.

Announcement of EIR Receipt

Gland Pharma promptly shared the positive news through a filing with the Bombay Stock Exchange (BSE). In the statement, the company confirmed the receipt of the Establishment Inspection Report, officially marking the conclusion of the inspection.

Significance of EIR

The EIR holds immense significance in the pharmaceutical realm. It serves as a testament to a company’s commitment to quality and adherence to regulatory requirements.

For Gland Pharma, this achievement not only validates its practices but also instills confidence in stakeholders and the industry at large.

Quality Assurance Practices at Pashamylaram Facility

The Pashamylaram Facility in Hyderabad, where the inspection took place, is a crucial component of Gland Pharma’s manufacturing capabilities.

The successful inspection underscores the company’s robust quality assurance practices, ensuring the production of safe and reliable pharmaceuticals.

Implications for Gland Pharma

The closure of the USFDA inspection brings forth positive implications for Gland Pharma. It not only solidifies the company’s reputation for quality but may also result in increased trust from consumers, partners, and investors.

Gland Pharma’s Product Portfolio

Gland Pharma’s extensive product portfolio is a testament to its commitment to addressing diverse medical needs.

The company’s offerings encompass a wide array of pharmaceutical solutions, showcasing its versatility and expertise in the field.

Timeline of Gland Pharma’s Growth

Since its inception in 1978, Gland Pharma has achieved significant milestones.

A timeline highlighting key moments in the company’s growth journey showcases its resilience and adaptability in the ever-evolving pharmaceutical landscape.

USFDA Regulations for Medical Devices

The inspection at the Pashamylaram Facility specifically focused on compliance with USFDA regulations for Medical Devices.

Understanding these regulations provides insight into the meticulous standards upheld by Gland Pharma.


  1. What does the Establishment Inspection Report (EIR) signify for Gland Pharma?
    • The EIR signifies the successful closure of the USFDA inspection, validating Gland Pharma’s adherence to quality and regulatory standards.
  2. How does the inspection outcome impact Gland Pharma’s reputation?
    • The positive outcome enhances Gland Pharma’s reputation, fostering trust among consumers, partners, and investors.
  3. Can you elaborate on the significance of the USFDA regulations for Medical Devices?
    • The regulations ensure that companies comply with strict standards, emphasizing the safety and efficacy of medical devices.
  4. What is the scope of Gland Pharma’s pharmaceutical product portfolio?
    • Gland Pharma offers a diverse range of products, including injectables, vials, ampoules, pre-filled syringes, and more.
  5. How does Gland Pharma plan to leverage this success for future growth?
    • While specific plans may not be detailed, the positive inspection outcome positions Gland Pharma for potential growth opportunities in the pharmaceutical sector

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
YouTube Icon